Can a Blood Marker Predict Atezolizumab–Bevacizumab Outcomes in Liver Cancer?
Direct answer: Not yet. A Japanese study found that higher pretreatment serum full-length glypican-3, or FL-GPC3, was associated with poorer disease control and shorter survival among 102 patients with unresectable hepatocellular carcinoma who received atezolizumab plus bevacizumab. The finding is clinically interesting, but it comes from a single-center retrospective cohort. FL-GPC3 is still a candidate biomarker, not an approved companion diagnostic or a stand-alone reason to start, stop, or change treatment.
Why patients are looking for a predictive blood test
People facing unresectable hepatocellular carcinoma often receive the same broad treatment recommendation but experience very different outcomes. This leads to an understandable question: can a blood test tell in advance whether immunotherapy combined with an anti-angiogenic drug is likely to work?
The new study provides a clue, not a personal forecast. An association seen across a group cannot determine what will happen to one individual. Treatment decisions still depend on tumor distribution, liver reserve, portal hypertension and bleeding risk, prior therapies, performance status, other illnesses, and changes on serial imaging.
What the Japanese study actually found
Researchers at Osaka Metropolitan University reviewed 102 patients treated with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma between 2020 and 2025. Patients with higher baseline serum FL-GPC3 had a lower disease-control rate and shorter progression-free and overall survival. In multivariable analyses, a high FL-GPC3 concentration remained associated with worse outcomes.
The original paper was published in Scientific Reports on September 7, 2026, and the university issued its research summary on September 28. The evidence stage is observational evidence. This was not a randomized trial testing an FL-GPC3-guided strategy, and the study did not show that changing treatment because of an FL-GPC3 result improves outcomes.
That distinction matters. A prognostic marker may identify patients who tend to have a more difficult course. A predictive marker should help distinguish who benefits from one treatment rather than another. This retrospective analysis cannot by itself establish FL-GPC3 as a validated predictive test.
What a Japanese specialist may reassess
- How secure is the diagnosis? A review may check the basis for the hepatocellular carcinoma diagnosis, pathology when available, disease stage, vascular invasion, and extrahepatic spread.
- How much liver reserve remains? Child-Pugh classification, bilirubin, albumin, coagulation, ascites, and the background liver disease can materially change treatment tolerance and prognosis.
- Is bevacizumab risk adequately assessed? Varices, recent bleeding, blood pressure, proteinuria, wound healing, and other contraindications or cautions deserve review before and during treatment.
- Has response been evaluated in context? Contrast-enhanced CT or MRI, tumor markers, symptoms, and the timing of scans should be reviewed together rather than relying on one laboratory value.
- When should the next line be discussed? If there is confirmed progression or unacceptable toxicity, the team can reconsider sequencing based on prior therapy, organ function, and options available in the patient’s country.
Who may benefit from a structured second opinion?
A written second opinion can be useful when hospitals disagree about the initial systemic plan, imaging and tumor-marker trends do not align, liver function or bleeding risk complicates treatment, or progression requires a new sequence of decisions. It can also be useful when the outcome is confirmation that the current plan is reasonable.
A remote review is not an emergency service. Vomiting blood, black stools, worsening confusion, rapidly increasing jaundice, persistent fever, or severe abdominal pain require prompt local assessment. Care should not be delayed while waiting for an overseas opinion.
Records that make the review more useful
- The pathology report or the clinical basis for diagnosis
- Original contrast-enhanced CT or MRI files in DICOM format, plus reports
- Recent liver function, coagulation, blood count, kidney function, and urine protein results
- AFP, PIVKA-II/DCP, and other marker trends
- Endoscopy findings and any history of varices or bleeding
- A dated list of treatments, doses, adverse effects, and current medication
- Three to five specific questions for the reviewing specialist
Practical next step
First define the decision that needs to be made now: whether treatment can safely start, whether the present regimen should continue, or how to approach confirmed progression. A Japan Expert Second Opinion can review diagnosis, liver reserve, bleeding risk, imaging interpretation, and treatment sequence. The written opinion should then be discussed with the hepatology and oncology team responsible for local care.
A second opinion may recommend more information, suggest an alternative, or support the current plan. It is a medical decision tool. It does not guarantee a different recommendation, access to an experimental treatment, or a need to travel to Japan.
Frequently asked questions
Does a high FL-GPC3 level mean atezolizumab plus bevacizumab will not work?
No. The study found a group-level association. It cannot classify an individual patient as a responder or non-responder.
Is FL-GPC3 already a routine clinical test?
Not for selecting this treatment. In this context it remains a research biomarker and should not be presented as an approved companion diagnostic.
Is tissue GPC3 positivity the same as serum FL-GPC3?
No. Tissue expression, serum concentration, assay method, and cutoff are different concepts and should not be used interchangeably.
Is the goal of a Japanese second opinion to find a new drug?
Usually the first goal is to verify diagnosis, liver function, bleeding risk, response assessment, and sequencing. Approved therapies and clinical trials must be evaluated separately.
Must the patient travel to Japan?
No. Many recommendations can first be discussed with the treating team at home. Travel should be considered only if a specific evaluation or treatment requires it.
Risk notice
This article is for medical education and decision support. It does not provide a diagnosis, prescription, eligibility decision, or individual outcome prediction. Do not post medical records, imaging, or identity information in public comments.
Primary sources
- Osaka Metropolitan University: New candidate predictive biomarker in hepatocellular carcinoma, September 28, 2026.
- Clinical relevance of serum full-length glypican-3 in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, Scientific Reports, September 7, 2026.
Evidence checked: September 28, 2026.
Japan Expert Second Opinion: A structured written review can help organize the questions to take back to the local treating team. Medical information should be transferred only through a private, secure process.